Genocea Biosciences (NASDAQ:GNCA) Research Coverage Started at StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report published on Saturday. The firm issued a sell rating on the biotechnology company's stock.
斯托克新聞網在週六發佈的一份報告中對Genocea Biosciences(納斯達克：GNCA-GET評級)的股票進行了報道。該公司對這家生物技術公司的股票發佈了賣出評級。
Genocea Biosciences Price Performance
Genocea Bioscions價格表現
Shares of Genocea Biosciences stock opened at $0.01 on Friday. The firm has a market cap of $557,385.66, a price-to-earnings ratio of -0.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 52-week low of $0.01 and a 52-week high of $2.16. The stock has a 50-day simple moving average of $0.01 and a 200-day simple moving average of $0.34.
Genocea Biosciences的股票上週五開盤報0.01美元。該公司市值為557,385.66美元，本益比為-0.02，貝塔係數為1.96。該公司的債務權益比為0.24，流動比率為1.35，速動比率為1.35。Genocea Biosciences的52周低點為0.01美元，52周高位為2.16美元。該股的50日簡單移動均線切入位為0.01美元，200日簡單移動均線切入位為0.34美元。
Institutional Investors Weigh In On Genocea Biosciences
機構投資者參與Genocea Bioscions
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC bought a new position in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 9.31% of the company's stock.
一家對沖基金最近購買了Genocea Biosciences股票的新股份。根據Acadian Asset Management LLC最近提交給美國證券交易委員會的13F檔案，該公司在第四季度購買了Genocea Biosciences，Inc.(納斯達克代碼：GNCA-GET Rating)的一個新頭寸。該基金購買了這家生物技術公司21,741股股票，價值約25,000美元。機構投資者和對沖基金持有該公司9.31%的股票。
About Genocea Biosciences
關於Genocea生物科學
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物製藥公司，發現和開發新型癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免費獲取StockNews.com關於基因組生物科學的研究報告(GNCA)
- 達頓餐廳走低通脹之路
- 這3只股票為何在9月火爆開盤
- 通貨膨脹沒有差別，但它的影響有差別
- 3只被降級的必備股票放在你的觀察名單上
- 這是對第三季度收益報告季節的預期
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。